Physician profile
Nathaniel Carter
NPI 1902863566
$1,701.77
in general payments reported to CMS, 2019-2025
11 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $60.09 · 2021: $93.63 · 2022: $189 · 2023: $296 · 2024: $42.28 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $409.90 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $219.61 | 2020-2023 | Uplizna |
| Lundbeck LLC | $199.35 | 2024-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $151.50 | 2019-2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $145.55 | 2019-2022 | |
| Genentech USA, INC. | $145.16 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Emd Serono, INC. | $129.44 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $120.00 | 2025 | Zeposia |
| Eisai INC. | $104.81 | 2019 | |
| Celgene Corporation | $51.45 | 2022-2025 | Zeposia |
| Abbvie INC. | $25.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.